Labiotech.eu

News and Trends 16 Jul 2015

Sanofi’s Extreme Makeover gives prominence to Genzyme

There seems to be a tendency towards revolution amongst Sanofi’s CEOs. Olivier Brandicourt, Managing director of the French drugmaker since his €4.1M golden handshake with the company, has come up with a restructuration plan that will reduce Sanofi’s business units from seven to five. The French businessman expects this reorganization will help the company to […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Jul 2015

A Brand New Feature on Labiotechmap for our 3000 lovely Users

Are you guys kidding us ??? There are now over 3000 users on Labiotechmap.com! You have no idea how happy that makes us and how thankful we are! You guys are truly AMAZING 😀 On this special occasion we would like to let you guys know we added a brand new feature to make Labiotechmap even […]

July 16, 2015 - 1 minutemin - By Alexandre Lowrey

News and Trends 16 Jul 2015

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

Immunocore Limited, just announced that it has secured a £205 million financing (€293 m) from private investors to push forward its T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune diseases. This substantial amount of cash not only embodies the largest private investment ever made in Europe by a biotech company, but also the second […]

July 16, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

How Servier saved Cellectis, the French CAR-T Miracle

Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months away from bankruptcy, mainly because of the competing gene-editing technology CRISPR. How and why did Servier save them? Let’s find out. Cellectis was founded in 1999 in Paris and […]

July 15, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 15 Jul 2015

Ferring bets on bacteriophages to treat inflammatory bowel disease

Bacteriophages have been instinctively killing bacteria for millions of years. These natural bacteria predators represent a potential alternative to antibiotics and Ferring Pharmaceuticals wants to use them against inflammatory bowel disease. The Swiss pharma joined forces with phages specialist Intralytix to manufacture these viruses for clinical purposes. Bacteriophages can be very selective when it comes […]

July 15, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Jul 2015

Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo

A new success for personalized medicines against cancer! AstraZeneca and Qiagen’s collaboration has achieved a major milestone after receiving the FDA’s approval of Iressa, a first-line treatment for a common form of lung cancer. The drug candidate is paired with Qiagen’s therascreen EGRF test as a companion diagnostic test. There is no doubt: the future […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jul 2015

GSK becomes the first Pharma to collaborate with the Francis Crick Institute

The future Francis Crick Institute has established its first industrial collaboration, even before opening its doors. And the lucky nominee couldn’t have been any other than GlaxoSmithKline, the UK’s largest pharmaceutical company. The partners are seeking to better understand human diseases, hoping that the research will lead to innovative drugs against a broad range of disorders. The […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Jul 2015

Newron’s ressurection story continues with a FDA Orphan Drug designation

New success for Newron Pharmaceuticals. The FDA approved Orphan Drug designation to its new chemical entity Sarizotan, designed to treat patients suffering from Rett syndrome. This decision fits the one from the European Medicine Agency, whose Committee for Orphan Medical Products positively reviewed the drug last month. The Italian pharma company Newron with a market […]

July 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Jul 2015

Probiodrug bets on basic research with Harvard’s collaboration

Probiodrug will provide research funding to the laboratory of Cynthia Ann Lemere in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical School. Dr. Lemere is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s disease. […]

July 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Jul 2015

Researchers found the missing key factor to unleash the potential of iPS Cells

When the Nobel Prize-winning Dr. Shinya Yamanaka succeeded to generate induced pluripotent cells (iPS cells) from specialized adult cells, the field of stem cells was completely revolutionized. Since Yamanaka’s paper on adult mouse fibroblasts back in 2006, scientists have been able to perform cellular reprogramming, but the process still isn’t mastered yet. One of the […]

July 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Jul 2015

ReNeuron backed by First-Class Investor Woodford to advance Stem Cell Therapy

The stem cell therapy developer ReNeuron raised €96M to conduct further clinical trials of its pipeline, and more specifically to pursue potential stroke, eye disease, and cancer treatments. The financial placement is supported by the already major shareholder Woodford Investment Management, allowing the latter to possess more than one-third of the company shares. ReNeuron, a […]

July 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Jul 2015

After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

Horizon Pharma is getting anxious and has offered the substantial amount of €2.7Bn to buy its American competitor Depomed. The Irish drug-maker plans to add the US-based firm to its shopping list just after enrolling Hyperion Therapeutics, the company that was purchased only one month ago. Dublin-based Horizon has been pursuing Depomed lately, but the American company is playing […]

July 13, 2015 - 1 minutemin - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Sanofi’s Extreme Makeover gives prominence to Genzyme

A Brand New Feature on Labiotechmap for our 3000 lovely Users

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

How Servier saved Cellectis, the French CAR-T Miracle

Ferring bets on bacteriophages to treat inflammatory bowel disease

Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo

GSK becomes the first Pharma to collaborate with the Francis Crick Institute

Newron’s ressurection story continues with a FDA Orphan Drug designation

Probiodrug bets on basic research with Harvard’s collaboration

Researchers found the missing key factor to unleash the potential of iPS Cells

ReNeuron backed by First-Class Investor Woodford to advance Stem Cell Therapy

After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!